Quinaglute, Nuedexta(quinidine)
Cardioquin, Nuedexta, Quinidine (quinidine) is a small molecule pharmaceutical. Quinidine was first approved as Quinaglute on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, and cardiac arrhythmias in the USA. It has been approved in Europe to treat neurobehavioral manifestations. It is known to target potassium voltage-gated channel subfamily H member 5, potassium channel subfamily K member 5, potassium voltage-gated channel subfamily H member 1, potassium channel subfamily T member 1, potassium channel subfamily T member 2, potassium channel subfamily K member 18, potassium channel subfamily K member 6, equilibrative nucleoside transporter 4, potassium channel subfamily K member 16, potassium channel subfamily K member 10, potassium voltage-gated channel subfamily A member 5, potassium voltage-gated channel subfamily A member 4, sodium channel protein type 5 subunit alpha, potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily D member 2, and potassium channel subfamily U member 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Combinations
Nuedexta (generic drugs available since 1982-01-01)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dextromethorphan hydrobromide
+
Quinidine sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NUEDEXTA | Avanir Pharmaceuticals | N-021879 RX | 2010-10-29 | 1 products, RLD, RS |
Quinidine gluconate
Quinidine polygalacturonate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CARDIOQUIN | Pharmaceutical Research Associates Inc | N-011642 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Quinidine sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QUINIDEX | WYETH PHARMS INC | N-012796 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nuedexta | New Drug Application | 2019-06-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| atrial fibrillation | EFO_0000275 | D001281 | I48.0 |
| atrial flutter | EFO_0003911 | D001282 | — |
| cardiac arrhythmias | EFO_0004269 | D001145 | I49.9 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 6 | 1 | 1 | 8 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | 2 | 1 | 2 | 6 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | 1 | 1 | 1 | 4 |
| Pseudobulbar palsy | D020828 | EFO_1001131 | — | — | — | 1 | 3 | — | 4 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | 1 | — | 2 |
| Traumatic brain injuries | D000070642 | — | S06 | — | — | 1 | 1 | — | 2 |
| Metabolic clearance rate | D008657 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | 1 | 4 | — | 2 | 6 |
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | 1 | 2 | 1 | — | — | 3 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | — | 1 | 3 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 3 | — | — | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 3 | — | — | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 2 | 1 | — | — | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | — | — | 2 |
| Ventricular fibrillation | D014693 | HP_0001663 | I49.01 | — | — | 2 | — | — | 2 |
| Brugada syndrome | D053840 | Orphanet_130 | I49.8 | — | — | 1 | — | 1 | 2 |
| Huntington disease | D006816 | Orphanet_399 | G10 | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | — | — | 2 |
| Malaria | D008288 | EFO_0001068 | B54 | — | 1 | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | — | 1 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | 1 | — | — | — | 1 |
| Dyskinesias | D020820 | HP_0002310 | G24 | — | 1 | — | — | — | 1 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | — | 1 | — | — | — | 1 |
| Neuralgia | D009437 | EFO_0009430 | — | — | 1 | — | — | — | 1 |
| Impulse control disruptive and conduct disorders | D007174 | — | F63.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | — | — | — | — | 9 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Hepatitis b | D006509 | — | — | 1 | — | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
| Constipation | D003248 | HP_0002019 | K59.0 | 1 | — | — | — | — | 1 |
| Covid-19 | D000086382 | — | U07.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | — | — | 1 | 1 |
| Vascular dementia | D015140 | — | F01 | — | — | — | — | 1 | 1 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | — | — | — | — | 1 | 1 |
| Brain injuries | D001930 | — | S06.9 | — | — | — | — | 1 | 1 |
| Lewy body disease | D020961 | EFO_0006792 | G31.83 | — | — | — | — | 1 | 1 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | — | — | — | 1 | 1 |
| Hyperhomocysteinemia | D020138 | — | — | — | — | — | — | 1 | 1 |
| Vitamin b 12 deficiency | D014806 | EFO_0000734 | E53.8 | — | — | — | — | 1 | 1 |
| Tauopathies | D024801 | — | — | — | — | — | — | 1 | 1 |
| Frontotemporal dementia | D057180 | HP_0002145 | G31.0 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Quinidine |
| INN | — |
| Description | Quinidine is a cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy. It has a role as an alpha-adrenergic antagonist, an antimalarial, an anti-arrhythmia drug, a sodium channel blocker, a muscarinic antagonist, a potassium channel blocker, a P450 inhibitor, an EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor, an EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor and a drug allergen. It derives from a hydride of a cinchonan. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12 |
Identifiers
| PDB | — |
| CAS-ID | 56-54-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1294 |
| ChEBI ID | 28593 |
| PubChem CID | 441074 |
| DrugBank | DB00908 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
KCNH5
KCNH5
KCNK5
KCNK5
KCNH1
KCNH1
KCNT1
KCNT1
KCNT2
KCNT2
KCNK18
KCNK18
KCNK6
KCNK6
SLC29A4
SLC29A4
KCNK16
KCNK16
KCNK10
KCNK10
KCNA5
KCNA5
KCNA4
KCNA4
SCN5A
SCN5A
KCNA7
KCNA7
KCND2
KCND2
KCNU1
KCNU1
Organism
Homo sapiens
Gene name
KCNH5
Gene synonyms
EAG2
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily H member 5
Protein synonyms
ether-a-go-go 2, Ether-a-go-go potassium channel 2, ether-a-go-go-related potassium channel 2, hEAG2, potassium channel, voltage gated eag related subfamily H, member 5, potassium voltage-gated channel, subfamily H (eag-related), member 5, Voltage-gated potassium channel subunit Kv10.2
Uniprot ID
Mouse ortholog
Kcnh5 (238271)
potassium voltage-gated channel subfamily H member 5 (Q920E3)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Quinidine
+
Dextromethorphan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Quinidine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,700 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,804 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use